PPPhilippe Paquet

Philippe Paquet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philippe Paquet has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Drug interactions with normal and TEN epidermal keratinocytes.

    by Philippe Paquet, Philippe Delvenne, Gerald E. Pierard

    Human epidermal keratinocytes (EKs) are metabolically involved in various drug transport mechanisms, as well as in detoxification or activation processes. The overall cell mechanisms of drug metabolization, and more specifically drug processing are reviewed in normal EKs. The overall drug metabolism involves different phases corresponding to the uptake, biotransformation and anti-transport steps. In EKs, both the enzymes and transportassociated proteins are different from those involved in the hepatocyte metabolism. Some cytochrome P450 enzymes and the flavin-containing mono-oxygenases are particularly involved in EKs. Basically, EKs represent key cells likely involved during the initial stage of drug-induced toxic epidermal necrolysis (TEN). Only limited advances have been made so far in this field. Nevertheless, mitigating EKs metabolic disturbances in TEN probably represent a promising specific treatment of the disease.


    • 1 December 2010
      • Vol. 65  (12) , 669-71

    [Primary and secondary prevention of skin cancers].

    by T Hermanns-Lê, F Henry, P Paquet, G E Piérard

    The occurrence of the vast majority of skin cancers depends on the environment, in particular on exposure to ultraviolet light radiations. Several modalities of primary and secondary prevention are possible. The first modality relies on proper covering or remaining hidden under shadow. Textiles exhibit some photoprotective function the efficacy of which depends on their nature and diverse modulating factors. Sun protection cream, some food habits, the intake of non steroidal anti-inflammatory drugs, and that of specific food complements are supposed to be beneficial at various levels.

    • 1 December 2010
      • Vol. 65  (12) , 696-9

    [How I explore...a skin tumor in a transplant patient].

    by P Quatresooz, M A Reginster, P Paquet, C Piérard-Franchimont, G E Piérard

    Immunosuppressive therapy associated with organ transplant leads to an increased risk to develop skin cancers. In such circumstances, squamous cell carcinomas and basal cell carcinomas represent the most frequent tumors. Other neoplasms include malignant melanoma, Merkel cell carcinoma and Kaposi disease. Histopathology is primordial in the establishment of the diagnosis. In addition, bioengineering devices and skin imaging methods are useful in establishing the risk of cancers and for detecting incipient tumoral lesions.

    • 1 November 2010
      • Vol. 65  (11) , 606-10

    [How I treat ... some skin conditions by cooling].

    by G Szepetiuk, C Piérard-Frachimont, P Paquet, T Hermanns-Lê, G E Piérard

    Cold application to the skin is commonly used in dermatology. The modalities of application are diversified and condition the temperature reached in the skin and the therapeutic result. Hense, the term cryotherapy without further precision remains little informative. The sensibility to cold of the diverse types of cutaneous cells is heterogeneous, as well as that of healthy and neoplastic tissues.

    • 1 November 2010
      • Vol. 65  (11) , 619-22

    [Actinic keratosis in tune with field photocarcinogenesis. A revisited concept].

    by P Quatresooz, P Paquet, G E Piérard

    Actinic keratosis should no more be considered as a single neoplasm calling for an individual treatment. The concept of actinic photocarcinogenesis presently turns upside down the perception of skin cancers induced by nonionizing electromagnetic radiations. Currently, the clinician should cope with the whole skin area that has been damaged by chronic exposures to the visible and the invisible spectrum of the light. The therapeutic archetypes are 5-fluorouracile 5% and imiquimod 5% carefully applied to the skin area.

  • Topical treatment options for drug-induced toxic epidermal necrolysis (TEN)

    by Philippe Paquet, Gérald E Piérard

    Drug-induced toxic epidermal necrolysis (TEN) is a dreadful skin condition. The mortality rate of 25 - 30% is mainly due to both metabolic failures and septicemia following loss of epidermal integrity. Topical treatments are important options in these patients. Topical TEN care includes specific bedding, debridement of epidermal necrosis, applications of bioactive skin substitutes or semi-synthetic and synthetic dressings, as well as antiseptic and antibiotic agents. In the early exudating phase of TEN, the use of airfluidized bed combined with gentle debridement are recommended. Next, an alternating pressure mattress and silver impregnated absorbent dressings should be used. During the re-epithelialization phase, antiseptic or antibiotic creams overlaid with nonadherent dressings favor an optimized moist and bacteria-controlled environment. A suitable topical treatment is mandatory in TEN. Skin care procedures must be managed according to the skin condition corresponding to the initial highly exudating/necrotic phase, the secondary moderately exudating stabilized phase and the later re-epidermization phase. Bedding modalities, debridement procedures, applications of bioactive, semi-synthetic and synthetic dressings (silver-impregnated or not) and antiseptic/antibiotic creams should be adapted accordingly.


    • 1 March 2010
      • Vol. 65  (3) , 113-4

    [Image of the month. Idiopathic calcinosis of the scrotum].

    by P Paquet, C Devillers, G Szepetiuk, P Quatresooz, G E Piérard

  • New Insights in Toxic Epidermal Necrolysis (Lyellʼs Syndrome)

    by Philippe Paquet, Gérald E. Piérard

    Drug-induced toxic epidermal necrolysis (TEN), also known as Lyell’s syndrome, is a life-threatening drug reaction characterized by extensive destruction of the epidermis and mucosal epithelia. The...


    • 1 December 2009
      • Vol. 64  (12) , 601-5

    [Case of the month. Acute generalized exanthematous pustulosis due to an iodinated contrast radiodiagnostic agent].

    by P Paquet, G Vandenbossche, A F Nikkels, F Henry, G E Piérard

    Iodinated contrast agents are frequently involved in delayed polymorphic adverse skin reactions. Acute generalized exanthematous pustulosis following administration of iodinated contrast agents is a rare but severe form of such reactions. The disease is characterized by the sudden occurrence of an erosive and pustular erythroderma with fever, leukocytosis and sometimes peripheral adenopathies and liver involvement. This condition is considered as an immunologic reaction, primarily involving T lymphocytes. The overall mortality reaches about 1%. Elucidating the differential diagnosis with other acute paroxysmal drug eruptions (toxic epidermal necrolysis, Steven-Johnson syndrome and drug hypersensitivity syndrome) is of paramount importance for establishing the adequate treatment of PEAG.

    • 1 August 2009
      • Vol. 64, 334-8

    [A range of targeted treatments using monoclonal antibodies in dermatology. Current and future practice].

    by C Piérard-Franchimont, P Quatresooz, P Paquet, A F Nikkels, G E Piérard

    Targeted therapies are focused on one or a few molecules particularly involved in specific diseases. Some inflammatory dermatoses and cutaneous neoplasia potentially benefit from these approaches. Nine monoclonal antibodies of interest in dermatology are presented according to the disorders where they have proven their efficacy. Biotherapies extend beyond monoclonal antibodies. A given effect, such as TNF-alpha antagonism, is indeed obtained by distinct drug classes. The interindividual differences in the therapeutic responses remain unpredictable, and there is no criteria of selection of patients who could benefit the most from these targeted medications.